NIDDK's Diabetes Grant Huddle: Open for Some Snooping
Published Date: 6/6/2025
Notice
Summary
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is holding a public meeting on October 8-9, 2025, to discuss important research and review grant applications. Scientists and researchers applying for funding will be affected, as their work and qualifications will be evaluated. The meeting is partly open to the public online, with no direct money changes announced but important decisions on research support are expected.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
NIDDK grant review for applicants
If you are a scientist or researcher applying for NIDDK funding, your grant application and personal qualifications will be reviewed during the closed session on October 9, 2025 from 10:00 a.m. to 5:00 p.m. The Board of Scientific Counselors will evaluate individual investigators’ qualifications and competence, and important decisions on research support are expected.
Public videocast and accommodations
The meeting is open to the public on October 8, 2025 from 10:00 a.m. to 5:00 p.m. and can be accessed via the NIH Videocast at https://videocast.nih.gov/. Individuals who plan to attend and need special assistance (for example, sign language interpretation) should notify the contact person Michael W. Krause, Ph.D., at (301) 402-4633 or [email protected] in advance.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-10334, National Institute of General Medical Sciences; Cancellation of Meeting
The National Institute of General Medical Sciences canceled a special meeting set for July 1, 2025, about Tribal Institutional Review Board awards. This meeting was moved from the National Cancer Institute to the Center for Scientific Review, so folks involved should watch for updates on when and where reviews will happen. No money changes or delays were mentioned, but staying tuned is key!
Next: 2025-10336, National Cancer Institute; Notice of Meeting
The National Cancer Institute is hosting a virtual meeting on July 16, 2025, to talk about their latest cancer research and clinical trials. Anyone interested can join online, share their thoughts, and learn about new plans that could shape cancer treatments. This is a great chance for researchers, patients, and the public to get involved without leaving home!